Twist Bioscience Corporation
$61.88
▲
1.35%
2026-04-21 09:58:00
www.twistbioscience.com
NMS: TWST
Explore Twist Bioscience Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.79 B
Current Price
$61.88
52W High / Low
$62.09 / $23.3
Stock P/E
—
Book Value
$7.44
Dividend Yield
—
ROCE
-24.75%
ROE
-16.79%
Face Value
—
EPS
$-1.27
Exp Qtr EPS
—
Sector
Healthcare
Industry
Diagnostics & Research
Employees
979
Beta
2.21
Debt / Equity
24.79
Current Ratio
3.78
Quick Ratio
3.33
Forward P/E
-25.42
Price / Sales
7.5
Enterprise Value
$2.85 B
EV / EBITDA
-25.3
EV / Revenue
7.29
Rating
Strong Buy
Target Price
$50.89
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Qiagen N.V. | NOT FOUND | — | — | 0.64% | 9.02% | 11.57% | $57.81 / $38.8 | $18.33 |
| 2. | Guardant Health, Inc. | $90.8 | — | $11.97 B | — | -25.56% | 348.42% | $120.74 / $36.36 | $-0.76 |
| 3. | Mainz Biomed N.V. | $0.47 | — | $5.89 M | — | -252.7% | -4.88% | $4.43 / $0.4 | $0.62 |
| 4. | FONAR Corporation | $18.8 | 15.61 | $117.93 M | — | 5.81% | 6.01% | $18.86 / $12 | $27.01 |
| 5. | ICON Public Limited Company | $114.42 | 15.51 | $8.76 B | — | 8.66% | 6.27% | $211 / $66.57 | $122.25 |
| 6. | IDEXX Laboratories, Inc. | $580.27 | 44.49 | $46.26 B | — | 61.76% | 66.2% | $769.98 / $402.85 | $20.14 |
| 7. | bioAffinity Technologies, Inc. | $2.69 | — | $12.87 M | — | -131.93% | -3.02% | $17.44 / $0.69 | $1.62 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 103.7 M | 99.01 M | 96.06 M | 92.79 M | 88.71 M | — |
| Operating Profit | -33.1 M | -29.93 M | -30.12 M | -41.56 M | -34.64 M | — |
| Net Profit | -30.51 M | -27.14 M | 20.39 M | -39.33 M | -31.59 M | — |
| EPS in Rs | -0.5 | -0.44 | 0.33 | -0.64 | -0.52 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 376.57 M | 312.97 M | 245.11 M | 203.56 M |
| Operating Profit | -136.26 M | -175.9 M | -206.9 M | -249.02 M |
| Net Profit | -77.67 M | -208.73 M | -204.62 M | -217.86 M |
| EPS in Rs | -1.27 | -3.4 | -3.34 | -3.55 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 641.86 M | 614.32 M | 776.4 M | 961.38 M |
| Total Liabilities | 168.9 M | 141.63 M | 152.97 M | 171.99 M |
| Equity | 472.96 M | 472.69 M | 623.43 M | 789.38 M |
| Current Assets | 332.97 M | 346.78 M | 424.26 M | 596.48 M |
| Current Liabilities | 91.41 M | 71.01 M | 73.32 M | 90.66 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -47.63 M | -64.09 M | -142.47 M | -124.39 M |
| Investing CF | -24.76 M | -3.07 M | 50.61 M | -232.93 M |
| Financing CF | 28.54 M | 6.89 M | 0.91 M | 270.53 M |
| Free CF | -75.63 M | -69.17 M | -170.25 M | -226.24 M |
| Capex | -28 M | -5.08 M | -27.78 M | -101.86 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 27.69% | 20.41% | — | — |
| Earnings Growth % | -2.01% | 6.08% | — | — |
| Profit Margin % | -66.69% | -83.48% | -107.02% | — |
| Operating Margin % | -56.2% | -84.41% | -122.33% | — |
| Gross Margin % | 42.61% | 36.61% | 41.38% | — |
| EBITDA Margin % | -46.16% | -72.45% | -103.99% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.